Invitrogen™ Opucolimab Recombinant Monoclonal Antibody

Opucolimab, also known as HLX20, is a recombinant human monoclonal antibody that targets the programmed death-ligand 1 (PD-L1), also referred to as CD274 or B7-H1. CD274 is a gene encoding a protein critical for immune checkpoint regulation. Located on chromosome 9, this protein is expressed on the surface of various cell types, including tumor cells, immune cells, and normal tissues. PD-L1 interacts with the PD-1 receptor on T cells to modulate immune responses, particularly by promoting self-tolerance and preventing autoimmunity. In the context of cancer, aberrant expression of CD274 allows tumor cells to evade immune surveillance, leading to immune escape. This mechanism has made CD274 a significant target for cancer immunotherapies, particularly immune checkpoint inhibitors such as pembrolizumab and nivolumab, which block the PD-1/PD-L1 interaction to restore anti-tumor immunity. Research on CD274 continues to reveal its role in various malignancies and its potential as a prognostic and therapeutic biomarker.